Inc. (NASDAQ:INCR) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition
Certain portions of our press release dated January 28, 2019, a copy of which is annexed hereto as Exhibit no. 99.1, are incorporated by reference herein, and are filed to this Item 2.02. They are as follows:
| ● | Portions of the 1st paragraph relating to net sales for the fourth quarter of 2018 and the full year ended December 31, 2018 |
| ● | The 2nd paragraph relating to net sales for the fourth quarter of 2018 and the full year ended December 31, 2018 (consisting of a table) |
| ● | The 3rd paragraph relating to European operations |
| ● | The 4th paragraph relating to United States operations |
Item 7.01 Regulation FD Disclosure
Certain portions of our press release dated January 28, 2019, a copy of which is annexed hereto as Exhibit no. 99.1, are incorporated by reference herein, and are filed to this Item 7.01 and Regulation FD. They are as follows:
| ● | The last sentence of the 1st paragraph relating to our plans to release operating results for the fourth quarter of 2018 and the full year ended December 31, 2018 |
| ● | The 5th paragraph relating to new product launches and our plans for anticipated sales growth |
| ● | The 6th paragraph relating to 2018 guidance and 2019 guidance |
| ● | The 8th paragraph relating to forward looking information |
| ● | The balance of such press release not otherwise incorporated by reference in Item 2.02. |
Item 9.01 Financial Statements and Exhibits.
99.1 Our press release dated January 28, 2019.
INTER PARFUMS INC Exhibit
EX-99.1 2 s115564_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE INTER PARFUMS,…
To view the full exhibit click here
About Inc. (NASDAQ:INCR)
INC Research Holdings, Inc. is a global contract research organization (CRO). The Company is focused on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services. The Company’s Clinical Development Services segment offers all clinical development services, including full-service global studies, as well as ancillary services, such as clinical monitoring, investigator recruitment, patient recruitment, data management, study reports to assist customers with their drug development process, quality assurance audits and specialized consulting services. The Company’s Phase I Services segment focuses on clinical development services for Phase I trials, which include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds.
